Wells Fargo raised the firm’s price target on Immunovant to $48 from $33 and keeps an Overweight rating on the shares, citing IMVT-1402’s positive Phase 1 safety data. The firm believes IMVT-1402 is differentiated within the class and should warrant scarcity value based on its emerging profile.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IMVT:
- Immunovant Announces Pricing of $450 Million Common Stock Financing
- Immunovant price target raised to $49 from $29 at BofA
- Immunovant price target raised to $50 from $33 at Citi
- Immunovant Announces Proposed Offering of $300 Million of Common Stock
- Immunovant announces $300M offering of common stock